文章：

Survival Outcomes in the Canadian Merkel Cell Carcinoma Population Between 2000 and 2018 and Descriptive Comparison with the American Joint Committee on Cancer 8th Edition Staging System—A Study from the Pan-Canadian Merkel Cell Collaborative

原文发布日期：6 October 2025

DOI: 10.3390/cancers17193238

类型: Article

开放获取: 是

英文摘要：

Background/Objectives: Merkel cell carcinoma (MCC) is an uncommon but aggressive skin malignancy with a rising incidence. Limited data exist on the survival of MCC patients in Canada. This study analyzes the survival of patients diagnosed with MCC in Canada between 2000 and 2018 compared to those reported by the American Joint Committee on Cancer (AJCC) 8th edition. Risk factors included in the database were sex, age, and immunosuppression.Methods: We conducted a multicenter retrospective cohort study including patients diagnosed with stage I–IV MCC aged ≥18 from 10 Canadian university centers and three provinces. We evaluated differences in survival compared to the cohort included in the AJCC 8th edition.Results: Among 899 patients diagnosed with MCC in Canada, 327 (36.4%) had stage I, 195 (21.7%) had stage II, 305 (33.9%) had stage III, and 72 (8.0%) had stage IV at presentation. When examining risk factors, 61.1% (549) were male, 10.2% (92) were immunosuppressed, and age at diagnosis was 75 years (±11). The five-year overall survival for patients diagnosed in Canada at stage I was 56.8%, stage IIA 54.0%, stage IIB 28.0%, stage IIIA 52.7%, stage IIIB 40.2%, and stage IV 13.9%.Conclusions: Survival from MCC is low in Canada across all stages. Compared to the AJCC 8th edition, patients diagnosed with MCC in Canada have similar survival rates, except for patients diagnosed with stage IIIB, who have lower survival rates in the AJCC 8th edition. Further research is needed to improve the survival of this rare malignancy.

摘要翻译： 

背景/目的：默克尔细胞癌是一种罕见但具有侵袭性的皮肤恶性肿瘤，其发病率呈上升趋势。目前关于加拿大默克尔细胞癌患者生存状况的数据有限。本研究分析了2000年至2018年间加拿大默克尔细胞癌确诊患者的生存情况，并与美国癌症联合委员会第八版分期系统报告的数据进行比较。数据库中包含的风险因素包括性别、年龄和免疫抑制状态。 方法：我们开展了一项多中心回顾性队列研究，纳入了来自加拿大10所大学医疗中心和三个省份、年龄≥18岁、诊断为I–IV期默克尔细胞癌的患者。我们评估了该队列与AJCC第八版纳入队列在生存率方面的差异。 结果：在加拿大确诊的899例默克尔细胞癌患者中，初诊时I期327例（36.4%），II期195例（21.7%），III期305例（33.9%），IV期72例（8.0%）。在风险因素分析中，男性占61.1%（549例），免疫抑制患者占10.2%（92例），确诊年龄为75岁（±11岁）。加拿大确诊患者的五年总生存率分别为：I期56.8%，IIA期54.0%，IIB期28.0%，IIIA期52.7%，IIIB期40.2%，IV期13.9%。 结论：加拿大各期默克尔细胞癌患者的生存率均较低。与AJCC第八版数据相比，加拿大默克尔细胞癌患者的生存率总体相似，但IIIB期患者在AJCC第八版中的生存率更低。需要进一步研究以提高这种罕见恶性肿瘤的生存率。

原文链接：

Survival Outcomes in the Canadian Merkel Cell Carcinoma Population Between 2000 and 2018 and Descriptive Comparison with the American Joint Committee on Cancer 8th Edition Staging System—A Study from the Pan-Canadian Merkel Cell Collaborative